OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Immunotherapy-based combinations in metastatic NSCLC
Aakash Desai, Solange Peters
Cancer Treatment Reviews (2023) Vol. 116, pp. 102545-102545
Open Access | Times Cited: 36
Aakash Desai, Solange Peters
Cancer Treatment Reviews (2023) Vol. 116, pp. 102545-102545
Open Access | Times Cited: 36
Showing 1-25 of 36 citing articles:
Beyond Chemoimmunotherapy in Advanced Non–Small Cell Lung Cancer: New Frontiers, New Challenges
Giannis Mountzios, Jarushka Naidoo, Chao Wang, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 11
Giannis Mountzios, Jarushka Naidoo, Chao Wang, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 11
Grade ≥ 3 hematologic adverse events of immunotherapy in advanced NSCLC patients: a systematic review and meta-analysis
Shuang Wang, Meng‐Ting Cai, Yajun Xiong, et al.
European Journal of Clinical Pharmacology (2025)
Closed Access | Times Cited: 1
Shuang Wang, Meng‐Ting Cai, Yajun Xiong, et al.
European Journal of Clinical Pharmacology (2025)
Closed Access | Times Cited: 1
E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells
Manman Liang, Zhengui Sun, Xingwu Chen, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 19
Manman Liang, Zhengui Sun, Xingwu Chen, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 19
Association between methyltransferase-like 3 and non-small cell lung cancer: pathogenesis, therapeutic resistance, and clinical applications
Xiaojuan Su, Yi Feng, Yi Qu, et al.
Translational Lung Cancer Research (2024) Vol. 13, Iss. 5, pp. 1121-1136
Open Access | Times Cited: 7
Xiaojuan Su, Yi Feng, Yi Qu, et al.
Translational Lung Cancer Research (2024) Vol. 13, Iss. 5, pp. 1121-1136
Open Access | Times Cited: 7
Lung Cancer Research and Treatment: Global Perspectives and Strategic Calls to Action
May-Lucie Meyer, S. Peters, Tony Mok, et al.
Annals of Oncology (2024)
Closed Access | Times Cited: 7
May-Lucie Meyer, S. Peters, Tony Mok, et al.
Annals of Oncology (2024)
Closed Access | Times Cited: 7
Clinical characteristics and novel strategies of immune checkpoint inhibitor rechallenge therapy for non-small cell lung cancer: a comprehensive review
Hao Zhang, Yujun Hu, Tingting Wu, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 4
Hao Zhang, Yujun Hu, Tingting Wu, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 4
Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial
Ming Gao, Xia Zhang, Huan Yan, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Ming Gao, Xia Zhang, Huan Yan, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Remote symptom monitoring with patient-reported outcomes and nudges during lung cancer immunotherapy in China (PRO-NET): protocol for a randomised controlled trial
Yiqi Xia, Xiaolong Guan, Zhenyu Shi, et al.
BMJ Open (2025) Vol. 15, Iss. 1, pp. e093374-e093374
Open Access
Yiqi Xia, Xiaolong Guan, Zhenyu Shi, et al.
BMJ Open (2025) Vol. 15, Iss. 1, pp. e093374-e093374
Open Access
Establishment and validation of a survival prediction model for stage IV non-small cell lung cancer: a real-world study
Keao Zheng, Junyan Zhang, Xu Tingting, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Keao Zheng, Junyan Zhang, Xu Tingting, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Discovery of novel small molecules targeting TGF-β signaling for the treatment of non-small cell lung cancer
Jie Zhang, Yi‐Chen Yin, Baozhen Wang, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117442-117442
Closed Access
Jie Zhang, Yi‐Chen Yin, Baozhen Wang, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117442-117442
Closed Access
High tumor mutation burden mitigates the negative impact of chemotherapy history on immune checkpoint blockade therapy
Ming Zheng
Seminars in Oncology (2025) Vol. 52, Iss. 2, pp. 152334-152334
Closed Access
Ming Zheng
Seminars in Oncology (2025) Vol. 52, Iss. 2, pp. 152334-152334
Closed Access
Identification of Genomic Instability-Associated LncRNAs as Potential Therapeutic Targets in Lung Adenocarcinoma
Vanessa G. P. Souza, Katya Benard, Greg L. Stewart, et al.
Cancers (2025) Vol. 17, Iss. 6, pp. 996-996
Open Access
Vanessa G. P. Souza, Katya Benard, Greg L. Stewart, et al.
Cancers (2025) Vol. 17, Iss. 6, pp. 996-996
Open Access
Ivonescimab in non-small cell lung cancer: harmonizing immunotherapy and anti-angiogenesis
Yan Zhang, Xinyu Liu, Shengxiang Ren
Expert Opinion on Biological Therapy (2025)
Closed Access
Yan Zhang, Xinyu Liu, Shengxiang Ren
Expert Opinion on Biological Therapy (2025)
Closed Access
Biological mechanisms and immunotherapy of brain metastases in non-small cell lung cancer
Shih Sheng Jiang, Fengzhu Guo, Lin Li
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189320-189320
Closed Access
Shih Sheng Jiang, Fengzhu Guo, Lin Li
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189320-189320
Closed Access
Neoadjuvant therapy for non-small cell lung cancer and esophageal cancer
Yunlong He
American Journal of Cancer Research (2024) Vol. 14, Iss. 3, pp. 1258-1277
Open Access | Times Cited: 3
Yunlong He
American Journal of Cancer Research (2024) Vol. 14, Iss. 3, pp. 1258-1277
Open Access | Times Cited: 3
A Review of the Molecular Determinants of Therapeutic Response in Non-Small Cell Lung Cancer Brain Metastases
Catherine Boldig, Kimberly Boldig, Sepideh Mokhtari, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 6961-6961
Open Access | Times Cited: 3
Catherine Boldig, Kimberly Boldig, Sepideh Mokhtari, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 6961-6961
Open Access | Times Cited: 3
Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview
Changjin Wu, Wentan Li, Hongyu Tao, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 193, pp. 104195-104195
Closed Access | Times Cited: 7
Changjin Wu, Wentan Li, Hongyu Tao, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 193, pp. 104195-104195
Closed Access | Times Cited: 7
From bench to bedside: an interdisciplinary journey through the gut-lung axis with insights into lung cancer and immunotherapy
David Dora, Emőke Szőcs, Ádám Soós, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
David Dora, Emőke Szőcs, Ádám Soós, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Immunotherapy Is a Good Standard Option for Patients With Malignant Pleural Mesothelioma, Despite the Real-World Results From Australia
Illaa Smesseim, Paul Baas
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 4, pp. 547-550
Open Access | Times Cited: 2
Illaa Smesseim, Paul Baas
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 4, pp. 547-550
Open Access | Times Cited: 2
Immunotherapy through the Lens of Non-Small Cell Lung Cancer
Robyn Stanley, Saoirse Flanagan, David O’ Reilly, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 2996-2996
Open Access | Times Cited: 4
Robyn Stanley, Saoirse Flanagan, David O’ Reilly, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 2996-2996
Open Access | Times Cited: 4
Carpal Tunnel Syndrome Associated with Immune Checkpoint Inhibitors
Alexander Yakobson, Keren Rouvinov, Aharon Y. Cohen, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 9, pp. 1340-1340
Open Access | Times Cited: 4
Alexander Yakobson, Keren Rouvinov, Aharon Y. Cohen, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 9, pp. 1340-1340
Open Access | Times Cited: 4
The role of CD8 PET imaging in guiding cancer immunotherapy
Jiani Zhang, Bulin Du, Yuxiang Wang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Jiani Zhang, Bulin Du, Yuxiang Wang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
RNA-seq and bulk RNA-seq data analysis of cancer-related fibroblasts (CAF) in LUAD to construct a CAF-based risk signature
Youjiao Si, Zhonghua Zhao, Xiangjiao Meng, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Youjiao Si, Zhonghua Zhao, Xiangjiao Meng, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockade
Alessio Cortellini, Claudia Zampacorta, Michele De Tursi, et al.
Pathologica (2024) Vol. 116, Iss. 4, pp. 222-231
Open Access | Times Cited: 1
Alessio Cortellini, Claudia Zampacorta, Michele De Tursi, et al.
Pathologica (2024) Vol. 116, Iss. 4, pp. 222-231
Open Access | Times Cited: 1
Newly emerged ROS1 rearrangement in a patient with lung adenocarcinoma following resistance to immune checkpoint inhibitors: a case report
Jian Wang, Bingyue Liu, Qinhong Zheng, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Jian Wang, Bingyue Liu, Qinhong Zheng, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
